Rosetta Inks Deals to Identify microRNA Biomarkers | GenomeWeb

Rosetta Genomics said this week that it has signed two new agreements to develop and validate microRNA-based diagnostics that use biomarkers obtained from body fluid samples.

The agreements are with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both of which are based in Israel. They will help Rosetta identify initial miRNA candidate biomarkers for cardiovascular indications, neurodegenerative diseases, women's health conditions, and the early detection of certain cancers, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.